GILD

#86
Gilead Sciences, Inc. - Common Stock
134.4 3 USD
-0.85%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
134.41
134.48
Yıllık Aralık
104.46
157.27
Günlük Değişim
-0.85%
Aylık Değişim
+5.06%
6 Aylık Değişim
+6.95%
Yıllık Değişim
+20.44%
Önceki Kapanış
135.5 8
Open
134.4 8
Düşük
134.4 1
High
134.4 8
Hacim
640
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler Temettüler
Çeyreklik Yıllık
  • Market Capitalization 166.9 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry İlaç Üreticileri - Genel
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
18.96
Fiyat/satışlar oranı
5.88
Hisse başına temettü
0.82
Temettü getirisi %
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

Haberler